

```

=> File .Biotech
=> s (alpha-1-acid glycoprotein or AAG or orosmucoïd or acute plasma protein#)
6 FILES SEARCHED...
L1      28602 (ALPHA-1-ACID GLYCOPROTEIN OR AAG OR OROSMUCOID OR ACUTE PLASMA
          PROTEIN#)

=> s L1 and (lipopolysaccharide or LPS or endotoxin#)
L2      3371 L1 AND (LIPOPOLYSACCHARIDE OR LPS OR ENDOTOXIN#)

=> s L2 and (remov? or purif? or prepar? or depyrogen?)
L3      3076 L2 AND (REMOV? OR PURIF? OR PREPAR? OR DEPYROGEN?)

=> s L3 and (resin or silica-based or fumed silica or hydrophil?)
L4      2076 L3 AND (RESIN OR SILICA-BASED OR FUMED SILICA OR HYDROPHIL?)

=> s L4 and (vir? inactivat? or treat? or disinfect?)
L5      2062 L4 AND (VIR? INACTIVAT? OR TREAT? OR DISINFECT?)

=> s L5 and (remov? endotoxin or lipopolysaccharide or LPS)
L6      1521 L5 AND (REMOV? ENDOTOXIN OR LIPOPOLYSACCHARIDE OR LPS)

=> s L6 and (anion exchange matrix or chromatog?)
L7      1446 L6 AND (ANION EXCHANGE MATRIX OR CHROMATOG?)

=> s L7 and (anion exchange matrix)
L8      4 L7 AND (ANION EXCHANGE MATRIX)

=> d L8 1-4 bib ab

```

```

L8      ANSWER 1 OF 4  USPATFULL on STN
AN      2003:221206  USPATFULL
TI      Mouse unable to express functional alpha-4 integrin protein, and methods
          for assaying compounds or agents for alpha-4 integrin protein antagonist
          activity and a genetic marker for evaluating efficacy of modulators of
          signaling activity of a VLA-4 receptor
IN      Wasel-Nielen, Monika, Bridgewater, NJ, UNITED STATES
          Kirschbaum, Bernhard, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
          Foster, Martyn, Loughborough, UNITED KINGDOM
          Polites, Gregory, Bridgewater, NJ, UNITED STATES
          Khorkova, Olga, Bridgewater, NJ, UNITED STATES
          Zhu, Bin, Bridgewater, NJ, UNITED STATES
PI      US 2003154499      A1      20030814
AI      US 2002-163899      A1      20020605 (10)
PRAI    GB 2001-24895      20011017
          US 2001-297112P      20010608 (60)
          US 2002-382927P      20020523 (60)
          US 2002-384109P      20020529 (60)
DT      Utility
FS      APPLICATION
LREP    ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE:
          D-303A, BRIDGEWATER, PA, 08807
CLMN    Number of Claims: 54
ECL     Exemplary Claim: 1
DRWN    25 Drawing Page(s)
LN.CNT  5627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Provided herein is a mouse that is unable to express functional alpha-4
          integrin protein, and methods for assaying agents for alpha-4 integrin
          antagonist activity, as well genetic markers for analyzing the efficacy
          of VLA-4 modulators, and particularly antagonists.

```

```

L8      ANSWER 2 OF 4  USPATFULL on STN
AN      2002:235983  USPATFULL
TI      Purification method
IN      More, John Edward, Elstree, UNITED KINGDOM

```

Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM  
PA National Blood Authority (non-U.S. corporation)  
PI US 2002128180 A1 20020912  
AI US 2002-82925 A1 20020226 (10)  
RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A  
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,  
UNKNOWN  
PRAI GB 1996-4921 19960308  
DT Utility  
FS APPLICATION  
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,  
MN, 55402  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of **removing**  
**endotoxin** from **preparation** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**  
**glycoprotein** which includes this **depyrogenation** step,  
and to the **depyrogenated** product and its clinical uses.

L8 ANSWER 3 OF 4 USPATFULL on STN

AN 2002:109017 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)

PI US 6387877 B1 20020514

WO 9732893 19970912

AI US 1999-142348 19990125 (9)

WO 1997-GB642 19970307

19990125 PCT 371 date

PRAI DE 1996-4921 19960308

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed,  
Abdel A.

LREP Schwegman, Lundberg, Woessner & Kluth, P.A.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of **removing**  
**endotoxin** from **preparations** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**  
**glycoprotein** which includes this deprogenation step, and to the  
**depyrogenated** product and its clinical uses.

L8 ANSWER 4 OF 4 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1997-470537 [43] WPIDS

DNC C1997-149481

TI **Removing** lipo-polysaccharide from alpha-1 glyco-protein  
containing composition - by contacting composition with finely divided  
non-toxic **resin**.

DC B04  
 IN LEWIN, D R; MORE, J E; ROTT, J  
 PA (NABL-N) NAT BLOOD AUTHORITY  
 CYC 23  
 PI WO 9732893 A1 19970912 (199743)\* EN 41p  
 RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: AU CA JP US  
 ZA 9701998 A 19971126 (199802) 39p  
 AU 9721023 A 19970922 (199804)  
 EP 885241 A1 19981223 (199904) EN  
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 AU 716333 B 20000224 (200020)  
 JP 2001500839 W 20010123 (200107) 36p  
 US 6387877 B1 20020514 (200239)  
 US 2002128180 A1 20020912 (200262)  
 ADT WO 9732893 A1 WO 1997-GB642 19970307; ZA 9701998 A ZA 1997-1998 19970307;  
 AU 9721023 A AU 1997-21023 19970307; EP 885241 A1 EP 1997-906282 19970307,  
 WO 1997-GB642 19970307; AU 716333 B AU 1997-21023 19970307; JP 2001500839  
 W JP 1997-531591 19970307, WO 1997-GB642 19970307; US 6387877 B1 WO  
 1997-GB642 19970307, US 1999-142348 19990125; US 2002128180 A1 Cont of WO  
 1997-GB642 19970307, Cont of US 1999-142348 19990125, US 2002-82925  
 20020226  
 FDT AU 9721023 A Based on WO 9732893; EP 885241 A1 Based on WO 9732893; AU  
 716333 B Previous Publ. AU 9721023, Based on WO 9732893; JP 2001500839 W  
 Based on WO 9732893; US 6387877 B1 Based on WO 9732893  
 PRAI GB 1996-4921 19960308  
 AB WO 9732893 A UPAB: 19971030

Removing lipopolysaccharide (LPS) from an  
 alpha -1-acid glycoprotein (  
 AAG) containing composition, comprises contacting the composition  
 with a finely divided non-toxic resin.

Also claimed are: (1) AAG substantially free of LPS  
 , having a LPS concentration of at most 0.1 (particularly <  
 0.050) Eu/mg AAG; (2) virus inactivated or  
 virus depleted Apo-AAG composition; (3) Apo-AAG for  
 use in therapy, or treatment of drug toxicity, and (4) a process  
 for purifying AAG comprising contacting an AAG  
 containing composition with an anion exchange  
 matrix, eluting an AAG enriched fraction from the matrix  
 and depyrogenating by contact with a divided non-toxic  
 particulate resin followed by elution of a LPS  
 depleted AAG fraction.

The resin is a non-substituted, particulate, inorganic,  
 hydrophilic or silane based resin, and comprises  
 fumed silica. The ratio of resin to  
 AAG protein is 50:1-0.2:1 (w/w), and in the depyrogenation  
 step the AAG concentration in solution is 0.1-250 g/l.

USE - The process is used for the purification of  
 AAG, giving compositions containing as little as 0.016 Eu/mg  
 AAG protein.

The Apo-AAG is particularly useful in the clinical  
 management of drug overdoses, e.g. in the cases of tricyclic  
 antidepressants where overdose can be lethal. The treatment of  
 drug toxicity is especially useful for overdoses of quinine, lignococaine,  
 propranolol, amitriptyline, desipramine and nortriptyline.

ADVANTAGE - As LPS is the causative agent of septic shock,  
 which is a major cause of morbidity following gram negative bacterial  
 infection, particularly in hospitalised and immunocompromised patients,  
 the presence of LPS in AAG compositions renders them  
 unsuitable for human therapy. Currently available methods of  
 purifying AAG are laborious and time consuming,  
 involving a large number of individual steps, and are unsuitable for large  
 scale preparative processes.

Dwg.0/2

=> s 17 and (depyrogenat? or inactivat? or treat?)

L9 1446 L7 AND (DEPYROGENAT? OR INACTIVAT? OR TREAT?)

=> s 19 and (Cohn fraction?)

L10 5 L9 AND (COHN FRACTION?)

=> dup rem l10

PROCESSING COMPLETED FOR L10

L11 5 DUP REM L10 (0 DUPLICATES REMOVED)

=> d l11 1-5 bib ab

L11 ANSWER 1 OF 5 USPATFULL on STN

AN 2003:283079 USPATFULL

TI ICAM-related protein

IN Gallatin, W. Michael, Mercer Island, WA, UNITED STATES

Vazeux, Rosemay, Seattle, WA, UNITED STATES

PI US 2003199423 A1 20031023

AI US 2002-163942 A1 20020605 (10)

RLI Continuation of Ser. No. US 2001-753436, filed on 3 Jan 2001, ABANDONED  
Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED  
Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,  
GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US  
1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.  
No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part  
of Ser. No. WO 1993-US787, filed on 26 Jan 1993, PENDING  
Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26  
May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,  
filed on 27 Jan 1992, ABANDONED

DT Utility

FS APPLICATION

LREP MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO,  
IL, 60606-6357

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 33 Drawing Page(s)

LN.CNT 7097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DNA sequences encoding a novel human intercellular adhesion molecule  
polypeptide (designated "ICAM-R") and variants thereof are disclosed  
along with methods and materials for production of the same by  
recombinant procedures. Binding molecules specific for ICAM-R and  
variants thereof are also disclosed as useful in both the isolation of  
ICAM-R from natural cellular sources and the modulation of  
ligand/receptor binding biological activities of ICAM-R.

L11 ANSWER 2 OF 5 USPATFULL on STN

AN 2002:235983 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority (non-U.S. corporation)

PI US 2002128180 A1 20020912

AI US 2002-82925 A1 20020226 (10)

RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A  
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,  
UNKNOWN

PRAI GB 1996-4921 19960308

DT Utility

FS APPLICATION

LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,  
MN, 55402

CLMN Number of Claims: 26

ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of removing  
endotoxin from preparation of alpha-  
1-acid glycoprotein (orosomucoid) by contact  
with a finely divided non-toxic resin such as fumed  
silica. The invention also relates to a purification  
process for alpha-1-acid  
glycoprotein which includes this depyrogenation step,  
and to the depyrogenated product and its clinical uses.

L11 ANSWER 3 OF 5 USPATFULL on STN

AN 2002:109017 USPATFULL

TI Purification method

IN More, John Edward, Elstree, UNITED KINGDOM  
Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)

PI US 6387877 B1 20020514  
WO 9732893 19970912

AI US 1999-142348 19990125 (9)  
WO 1997-GB642 19970307  
19990125 PCT 371 date

PRAI DE 1996-4921 19960308

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed,  
Abdel A.

LREP Schwegman, Lundberg, Woessner & Kluth, P.A.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of removing  
endotoxin from preparations of alpha-  
1-acid glycoprotein (orosomucoid) by contact  
with a finely divided non-toxic resin such as fumed  
silica. The invention also relates to a purification  
process for alpha-1-acid  
glycoprotein which includes this depyrogenation step, and to the  
depyrogenated product and its clinical uses.

L11 ANSWER 4 OF 5 USPATFULL on STN

AN 2001:176635 USPATFULL

TI Icam-related protein

IN Gallatin, W. Michael, Mercer Island, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States

PA ICOS Corporation (U.S. corporation)

PI US 2001029293 A1 20011011

AI US 2001-753436 A1 20010103 (9)

RLI Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED  
Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,  
GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US  
1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.  
No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part  
of Ser. No. WO 1993-US787, filed on 26 Jan 1993, UNKNOWN  
Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26  
May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,  
filed on 27 Jan 1992, ABANDONED

DT Utility

FS APPLICATION

LREP MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN, 6300 SEARS TOWER, 233 SOUTH  
WACKER DRIVE, CHICAGO, IL, 60606-6402  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 33 Drawing Page(s)  
LN.CNT 7122

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

L11 ANSWER 5 OF 5 USPATFULL on STN

AN 1999:150946 USPATFULL

TI Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein

IN Gallatin, W. Michael, Mercer Island, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States

PA ICOS Corporation, Bothwell, WA, United States (U.S. corporation)

PI US 5989843 19991123

AI US 1996-720420 19960927 (8)

RLI Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995, now patented, Pat. No. US 5837822 which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned And Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992 which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992

DT Utility

FS Granted

EXNAM Primary Examiner: Duffy, Patricia A.

LREP Marshall, O'Toole, Gerstein, Murray & Borun

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 39 Drawing Figure(s); 34 Drawing Page(s)

LN.CNT 7311

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Modulators of protein kinase C phosphorylation of human intercellular adhesion molecule polypeptide (designated "ICAM-R") are identified through novel methods.

=> s 19 and (filtrat? or pasteuriz?)

L12 1057 L9 AND (FILTRAT? OR PASTEURIZ?)

=> s 112 and (resin)

L13 781 L12 AND (RESIN)

=> s remov? and 113

L14 780 REMOV? AND L13

=> s depyrogen? and 114

L15 22 DEPYROGEN? AND L14

=> s 18 and 115

L16 2 L8 AND L15

=> s 110 and 115

L17 2 L10 AND L15

=> s 116 and 117  
L18 2 L16 AND L17

=> dis 118 1-2 bib ab

L18 ANSWER 1 OF 2 USPATFULL on STN  
AN 2002:235983 USPATFULL  
TI **Purification** method  
IN More, John Edward, Elstree, UNITED KINGDOM  
Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM  
PA National Blood Authority (non-U.S. corporation)  
PI US 2002128180 A1 20020912  
AI US 2002-82925 A1 20020226 (10)  
RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A  
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,  
UNKNOWN  
PRAI GB 1996-4921 19960308  
DT Utility  
FS APPLICATION  
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,  
MN, 55402  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 971  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to a method of **removing**  
**endotoxin** from **preparation** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**  
**glycoprotein** which includes this **depyrogenation** step,  
and to the **depyrogenated** product and its clinical uses.

L18 ANSWER 2 OF 2 USPATFULL on STN  
AN 2002:109017 USPATFULL  
TI **Purification** method  
IN More, John Edward, Elstree, UNITED KINGDOM  
Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM  
PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)  
PI US 6387877 B1 20020514  
WO 9732893 19970912  
AI US 1999-142348 19990125 (9)  
WO 1997-GB642 19970307  
19990125 PCT 371 date  
PRAI DE 1996-4921 19960308  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed,  
Abdel A.  
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 942  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to a method of **removing**  
**endotoxin** from **preparations** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**

glycoprotein which includes this deprogenation step, and to the  
depyrogenated product and its clinical uses.

=> s 116 and (drug toxic?)

L19 2 L16 AND (DRUG TOXIC?)

=> d is 119 1-2 bib ab

L19 ANSWER 1 OF 2 USPATFULL on STN

AN 2002:235983 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority (non-U.S. corporation)

PI US 2002128180 A1 20020912

AI US 2002-82925 A1 20020226 (10)

RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A  
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,  
UNKNOWN

PRAI GB 1996-4921 19960308

DT Utility

FS APPLICATION

LN.CNT 971

INCL INCLM: 514/002.000

INCLS: 514/012.000; 530/350.000; 530/412.000; 530/416.000

NCL NCLM: 514/002.000

NCLS: 514/012.000; 530/350.000; 530/412.000; 530/416.000

IC [7]

ICM: A01N037-18

ICS: A61K038-00; A61K038-16; C07K001-00; C07K014-00; C07K017-00;

A23J001-00; C07K016-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 2 USPATFULL on STN

AN 2002:109017 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)

PI US 6387877 B1 20020514

WO 9732893 19970912

AI US 1999-142348 19990125 (9)

WO 1997-GB642 19970307

19990125 PCT 371 date

PRAI DE 1996-4921 19960308

DT Utility

FS GRANTED

LN.CNT 942

INCL INCLM: 514/008.000

INCLS: 514/002.000; 530/384.000; 530/395.000; 530/412.000; 530/414.000;  
530/416.000; 530/417.000; 530/427.000; 530/829.000; 530/831.000;  
424/078.100; 424/078.110

NCL NCLM: 514/008.000

NCLS: 424/078.100; 424/078.110; 514/002.000; 530/384.000; 530/395.000;  
530/412.000; 530/414.000; 530/416.000; 530/417.000; 530/427.000;  
530/829.000; 530/831.000

IC [7]

ICM: A61K038-16

ICS: A61K031-74; C07K014-00

EXF 514/8; 514/2; 530/384; 530/395; 530/412; 530/414; 530/416; 530/417;

530/427; 530/829; 530/831; 424/78.1; 424/78.11

CAS INDEXING IS AVAILABLE FOR THIS PATENT.